Prescription Required
Erbitux 100mg Infusion is a targeted cancer therapy used to treat colorectal cancer and head & neck cancer. It contains Cetuximab (100mg), a monoclonal antibody that blocks epidermal growth factor receptor (EGFR), preventing cancer cell growth. It is administered as an intravenous (IV) infusion under medical supervision.
Consult your doctor about consuming alcohol with this drug.
Consult your doctor, as it may be unsafe during pregnancy due to potential harm to the baby.
Erbitux 100mg Infusion is likely unsafe for breastfeeding mothers, as it may pass into breastmilk and harm the baby.
Be cautious, as it may cause side effects that affect your ability to drive.
Generally safe, but consult your doctor if you have kidney disease.
Limited information available, so consult your doctor if you have liver disease.
Erbitux 100mg Infusion is a monoclonal antibody that specifically binds to receptors on cancer cells. Thus it flags the cancer cells for destruction by the bodys immune system. Targets and binds to EGFR (epidermal growth factor receptor) on cancer cells. Prevents tumor growth by blocking signals that promote cell division. Enhances the effectiveness of chemotherapy and radiation therapy in certain cancers.
Colorectal Cancer – Cancer of the large intestine or rectum, often associated with EGFR overexpression. Head & Neck Cancer – Includes cancers of the mouth, throat, and larynx, often treated with radiation. EGFR-Positive Tumors – Cancers that overproduce the epidermal growth factor receptor (EGFR), leading to uncontrolled growth.
Erbitux 100mg Infusion is a targeted cancer therapy that blocks EGFR, slowing the growth of colorectal and head & neck cancers. It is given intravenously and works best when combined with chemotherapy or radiation.
MBA in pharmaceutical management
Content Updated on
Saturday, 8 Feburary, 2025Prescription Required
Simplify your healthcare journey with Indian Government's ABHA card. Get your card today!
Create ABHA